Want to see FTH full AI Analyst Report?
Total Valuation
Faeth Therapeutics has a market cap or net worth of $826.89M. The enterprise value is -$38.00.
Market Cap$826.89M
Enterprise Value-$38.00
Share Statistics
Faeth Therapeutics has 25,840,425 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,840,425
Owned by Insiders5.14%
Owned by Institutions46.62%
Financial Efficiency
Faeth Therapeutics’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -110.88%.
Return on Equity (ROE)-1.13
Return on Assets (ROA)-0.92
Return on Invested Capital (ROIC)-110.88%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee0.00
Profits Per Employee-727.07K
Employee Count29
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Faeth Therapeutics is ―. Faeth Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.72
Price to Fair Value0.72
Price to FCF-0.66
Price to Operating Cash Flow-5.33
PEG Ratio0.02
Income Statement
In the last 12 months, Faeth Therapeutics had revenue of 0.00 and earned -21.09M in profits. Earnings per share was -16.72.
Revenue0.00
Gross Profit0.00
Operating Income-22.29M
Pretax Income-21.09M
Net Income-21.09M
EBITDA-20.91M
Earnings Per Share (EPS)-16.72
Cash Flow
In the last 12 months, operating cash flow was -33.86M and capital expenditures -6.00K, giving a free cash flow of -33.86M billion.
Operating Cash Flow-33.86M
Free Cash Flow-33.86M
Free Cash Flow per Share-1.31
Dividends & Yields
Faeth Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change294.57%
50-Day Moving Average26.41
200-Day Moving Average20.38
Relative Strength Index (RSI)60.61
Average Volume (3m)38.93K
Important Dates
Faeth Therapeutics upcoming earnings date is Nov 10, 2026, Before Open (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Faeth Therapeutics as a current ratio of 5.06, with Debt / Equity ratio of 0.34%
Current Ratio5.06
Quick Ratio5.06
Debt to Market Cap<0.01
Net Debt to EBITDA0.34
Interest Coverage Ratio-696.50
Taxes
In the past 12 months, Faeth Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Faeth Therapeutics EV to EBITDA ratio is -0.30, with an EV/FCF ratio of -0.31.
EV to Sales0.00
EV to EBITDA-0.30
EV to Free Cash Flow-0.31
EV to Operating Cash Flow-0.31
Balance Sheet
Faeth Therapeutics has $186.44M in cash and marketable securities with $592.00K in debt, giving a net cash position of $185.85M billion.
Cash & Marketable Securities$186.44M
Total Debt$592.00K
Net Cash$185.85M
Net Cash Per Share$7.19
Tangible Book Value Per Share$14.75
Margins
Gross margin is 2740.82%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin2740.82%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Faeth Therapeutics is $55.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$55.50
Price Target Upside385.99% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-564.79%